※ 출처: ClinicalTrials.gov
총 150건

해외임상승인현황 정보 :: 순번, 임상시험 제목, 적응증, 연구설계, 의뢰자/실시기관, 임상단계, NCT No, 개시일자
순번 임상시험 제목 적응증 연구설계 의뢰자/실시기관 임상단계 NCT No 개시일자
1 Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract Allergic Rhinitis|Allergic Asthma|Allergic Rhinoconjunctivitis|Allergy to House Dust Mite Biological: 3,000 MM09|Biological: 9,000 MM09|Other: Placebo sublingual Inmunotek S.L.|LAT Research|Xolomon Tree S.L. Phase 2|Phase 3 2023-04-01
2 A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) Diffuse Large B-Cell Lymphoma Drug: Epcoritamab|Drug: Cyclophosphamide|Drug: Rituximab|Drug: Vincristine|Drug: Doxorubicin|Drug: Prednisone AbbVie|Genmab Phase 3 2023-02-08
3 A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) Melanoma Biological: Pembrolizumab/Vibostolimab|Biological: Pembrolizumab Merck Sharp & Dohme LLC Phase 3 2023-01-19
4 Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) COVID-19, SARS-CoV-2 Biological: AZD5156 (Sentinel Safety Cohort)|Biological: Placebo (Sentinel Safety Cohort)|Biological: AZD7442 (EVUSHELD™) (Main Cohort)|Biological: AZD3152 (Main Cohort) AstraZeneca Phase 3 2022-12-16
5 A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation Alzheimers Disease|Dementia|Alzheimers Disease, Familial Drug: Gantenerumab|Drug: Matching Placebo (Gantenerumab) Washington University School of Medicine|Hoffmann-La Roche|Alzheimer's Association|National Institute on Aging (NIA)|Genentech, Inc. Phase 2|Phase 3 2022-12-02
6 A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis Atopic Dermatitis Drug: Upadacitinib|Drug: Dupilumab AbbVie Phase 3 2022-11-28
7 Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10) Pneumococcal Disease Biological: V116|Biological: PPSV23 Merck Sharp & Dohme LLC Phase 3 2022-11-07
8 Safety and Efficacy of RUTI® With the Standard of Treatment for Tuberculosis Tuberculosis, Pulmonary Biological: RUTI® Vaccine|Biological: Placebo Archivel Farma S.L. Phase 2 2022-10-29
9 A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above Respiratory Syncytial Virus Infections Biological: RSVPreF3 OA investigational vaccine|Drug: Placebo GlaxoSmithKline Phase 3 2022-10-28
10 A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis Atopic Dermatitis|Eczema Drug: Lebrikizumab|Drug: Placebo|Drug: Topical corticosteroid Eli Lilly and Company|Dermira, Inc. Phase 3 2022-10-18